SIX1 attenuates inflammation and rheumatoid arthritis by silencing MyD88-dependent TLR1/2 signaling
- 15 February 2022
- journal article
- research article
- Published by Elsevier BV in International Immunopharmacology
- Vol. 106, 108613
- https://doi.org/10.1016/j.intimp.2022.108613
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressorsNature Reviews Rheumatology, 2012
- Intranasal Administration of the TLR2 Agonist Pam2Cys Provides Rapid Protection against Influenza in MiceMolecular Pharmaceutics, 2012
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and ImmunityImmunity, 2011
- HMGB1, TLR and RAGE: a functional tripod that leads to diabetic inflammationEmerging Therapeutic Targets, 2011
- The OARSI histopathology initiative – recommendations for histological assessments of osteoarthritis in the ratOsteoarthritis and Cartilage, 2010
- Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritisImmunological Reviews, 2009
- The arthritis severity locusCia5dis a novel genetic regulator of the invasive properties of synovial fibroblastsArthritis & Rheumatism, 2008
- Chemokines and their receptors in rheumatoid arthritis: Future targets?Arthritis & Rheumatism, 2005
- Signaling DangerJournal of the American Society of Nephrology, 2004
- Six1is required for the early organogenesis of mammalian kidneyDevelopment, 2003